Open Questions: Other

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
79 questions found for field 'Other'
open ⚖ 1500
Mechanistic understanding**: How does amyloid disrupt DMN function?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding**: How does alpha-synuclein spread through autonomic networks?
📑 0.50 💥 0.50
open ⚖ 1500
How does the spreading pattern correlate with clinical progression?
📑 0.50 💥 0.50
open ⚖ 1500
How do environmental toxins interact with mitochondrial pathways?
📑 0.50 💥 0.50
open ⚖ 1500
Which combination of biomarkers provides optimal prodromal detection?
📑 0.50 💥 0.50
open ⚖ 1500
Single-nucleus sequencing
📑 0.50 💥 0.50
open ⚖ 1500
Light-sheet microscopy
📑 0.50 💥 0.50
open ⚖ 1500
AI-assisted diagnosis
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
What triggers the initial misfolding of alpha-synuclein in sporadic PD?
📑 0.50 💥 0.50
open ⚖ 1500
Can targeting propagation halt disease progression in established PD?
📑 0.50 💥 0.50
open ⚖ 1500
What is the normal physiological function of LRRK2, and how do pathogenic mutations disrupt it?
📑 0.50 💥 0.50
open ⚖ 1500
How do GBA mutations modify alpha-synuclein pathology and treatment response?
📑 0.50 💥 0.50
open ⚖ 1500
Can gene-specific therapies be developed for different genetic subtypes?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relative contribution of mitochondrial dysfunction to dopaminergic neuron loss?
📑 0.50 💥 0.50
open ⚖ 1500
Can pharmacological activation of mitophagy compensate for PINK1/PARKIN deficiency?
📑 0.50 💥 0.50
open ⚖ 1500
What is the timeline from prodromal to clinical PD diagnosis?
📑 0.50 💥 0.50
open ⚖ 1500
Can prodromal intervention prevent progression to overt PD?
📑 0.50 💥 0.50
open ⚖ 1500
What determines whether a patient develops tau versus TDP-43 pathology?
📑 0.50 💥 0.50
open ⚖ 1500
How do the different subtypes (bvFTD, svPPA, nfPPA) relate to specific proteinopathies?
📑 0.50 💥 0.50
open ⚖ 1500
What is the normal physiological function of progranulin in the brain?
📑 0.50 💥 0.50
open ⚖ 1500
Can tau-targeted therapies benefit FTD patients with tau pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Can progranulin replacement or upregulation restore function?
📑 0.50 💥 0.50
open ⚖ 1500
How does progranulin deficiency lead to selective neuronal vulnerability?
📑 0.50 💥 0.50
open ⚖ 1500
What modifies the phenotype between FTD, ALS, and FTD-ALS?
📑 0.50 💥 0.50
open ⚖ 1500
How do dipeptide repeats contribute to neurodegeneration in FTD?
📑 0.50 💥 0.50
open ⚖ 1500
Can targeting RNA foci or dipeptide repeats provide therapeutic benefit?
📑 0.50 💥 0.50
open ⚖ 1500
What fluid biomarkers distinguish FTD subtypes?
📑 0.50 💥 0.50
open ⚖ 1500
How can genetic carriers be identified before symptom onset?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal combination of biomarkers for clinical trials?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise molecular switches that determine pathology type?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetic modifiers influence fate decisions?
📑 0.50 💥 0.50
open ⚖ 1500
Can we intervene to redirect pathology type?
📑 0.50 💥 0.50
open ⚖ 1500
What role does neuronal activity play in pathology selection?
📑 0.50 💥 0.50
open ⚖ 1500
Why have many neuroprotective phase II/III ALS trials failed despite strong preclinical rationale?
📑 0.50 💥 0.50
open ⚖ 1500
Cell Type Decomposition
📑 0.50 💥 0.50
open ⚖ 1500
Neuronal Subtypes
📑 0.50 💥 0.50
open ⚖ 1500
Glial Cell Populations
📑 0.50 💥 0.50
open ⚖ 1500
Epigenomic Data
📑 0.50 💥 0.50
open ⚖ 1500
Metabolomics
📑 0.50 💥 0.50
open ⚖ 1500
Prenatal to Adult Trajectories
📑 0.50 💥 0.50
open ⚖ 1500
Developmental Disorders
📑 0.50 💥 0.50
open ⚖ 1500
Critical Periods
📑 0.50 💥 0.50
open ⚖ 1500
Alzheimer's Disease
📑 0.50 💥 0.50
open ⚖ 1500
Parkinson's Disease
📑 0.50 💥 0.50
open ⚖ 1500
Aging Consortium
📑 0.50 💥 0.50
open ⚖ 1500
Spatial Transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Interactive Visualizations
📑 0.50 💥 0.50
open ⚖ 1500
iPSC Banks:
📑 0.50 💥 0.50
open ⚖ 1500
Single-Cell Atlas:
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal Cohorts:
📑 0.50 💥 0.50
open ⚖ 1500
Open Science Platforms:
📑 0.50 💥 0.50
open ⚖ 1500
Single-molecule array (Simoa)
📑 0.50 💥 0.50
open ⚖ 1500
Mass spectrometry
📑 0.50 💥 0.50
open ⚖ 1500
Multiplex platforms
📑 0.50 💥 0.50
open ⚖ 1500
Point-of-care devices
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell proteomics
📑 0.50 💥 0.50
open ⚖ 1500
Spatial proteomics
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal proteomics
📑 0.50 💥 0.50
open ⚖ 1500
Integration with genomics
📑 0.50 💥 0.50
open ⚖ 1500
Multi-omics integration
📑 0.50 💥 0.50
open ⚖ 1500
Targeted therapies
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Early detection
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Disease-modifying trials
📑 0.50 💥 0.50
open ⚖ 1500
Digital phenotyping
📑 0.50 💥 0.50
open ⚖ 1500
Advance CGC-100 to clinical trials
📑 0.50 💥 0.50
open ⚖ 1500
Expand pipeline
📑 0.50 💥 0.50
open ⚖ 1500
Strategic partnerships
📑 0.50 💥 0.50
open ⚖ 1500
Geographic expansion
📑 0.50 💥 0.50
open ⚖ 1500
Acquisition opportunities
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic understanding
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Treatment targeting
📑 0.50 💥 0.50
open ⚖ 1500
Individual variation
📑 0.50 💥 0.50
open ⚖ 1500
Network repair
📑 0.50 💥 0.50
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map